Looking for motivated, inflammasome experts to join our growing company!
NodThera is focused on the discovery and development of next generation NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation. We are building a pipeline of small molecule NLRP3 inhibitors through a highly differentiated, next generation approach that builds on and enhances existing understanding of NLRP3 biochemistry and its role in inflammation. The Company recently raised $40 million from Sofinnova Partners, 5AM Ventures, Epidarex Capital and F-Prime Capital Partners.
To apply for this job please visit nodthera.com.